Patents Examined by Christian C Boesen
  • Variant nucleic acid libraries for antibody optimization
    Patent number: 11492728
    Abstract: Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: November 8, 2022
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventor: Aaron Sato
  • Variant nucleic acid libraries for GLP1 receptor
    Patent number: 11492727
    Abstract: Provided herein are methods and compositions relating to glucagon-like peptide-1 receptor (GLP1R) libraries having nucleic acids encoding for a scaffold comprising a GLP1R binding domain. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: November 8, 2022
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventors: Ray Tabibiazar, Aaron Sato, Pankaj Garg, Qiang Liu, Fumiko Axelrod
  • Fibronectin type III domain based scaffold compositions, methods and uses
    Patent number: 11479880
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: October 25, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Steven Jacobs, Karyn O'Neil
  • Triple vector for expressing antibody molecules in full therapeutic format
    Patent number: 11479879
    Abstract: A triple expression vector is disclosed for expressing an antibody molecule comprising an Fc domain in prokaryotic cells and in eukaryotic cells. The triple expression vector comprises a polynucleotide encoding an Fc domain; a polynucleotide encoding a phage coat protein; a cloning site for cloning genes encoding an antibody molecule or a part thereof wherein the antibody molecule or part thereof does not comprise an Fc domain; a prokaryotic secretion signal sequence and a eukaryotic secretion signal sequence, or a secretion signal sequence that drives efficient secretion in both prokaryotic and eukaryotic cells; a promoter for mediating expression in eukaryotic cells; and a stop codon for preventing expression of the phage coat protein in eukaryotic cells.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: October 25, 2022
    Assignees: argenx BV, FAIRJOURNEY BIOLOGICS
    Inventors: Maria Gonzalez Pajuelo, Johannes Joseph Wilhelmus De Haard
  • Display library process
    Patent number: 11479877
    Abstract: Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: October 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Robert Charles Ladner, Shannon Hogan, Kristin L. Rookey
  • Compositions and methods for rapid production of versatile nanobody repertoires
    Patent number: 11447891
    Abstract: Provided are compositions and methods for producing large repertoires of recombinant nanobodies with high affinities and specificities against any antigen. Included are methods for making and identifying nanobodies produced by camelids, the nanobodies themselves, modifications of the nanobodies, expression vectors encoding the nanobodies, cDNAs encoding the nanobodies, cells comprising the expression vectors and/or cDNA, and methods of making the nanobodies recombinantly. Antigen-specific nanobodies and antigen binding fragments thereof having a Kd for the antigen in a sub-micromolar range are provided.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: September 20, 2022
    Assignee: The Rockefeller University
    Inventors: Michael P. Rout, Brian T. Chait
  • Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
    Patent number: 11447563
    Abstract: Methods are provided for identifying and selecting antibodies that are internalized into cells via the macropinocytosis pathway. Additionally antibodies that are internalized via this pathway are provided as well as immunoconjugates comprising such antibodies.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: September 20, 2022
    Assignee: The Regents of the University of California
    Inventor: Bin Liu
  • Systems and methods for massively parallel combinatorial analysis of single cells
    Patent number: 11441240
    Abstract: Provided herein are methods that enable parallel evaluation of multiple functional nucleic acids in individual cells or subpopulations of cells, in the context of incubation with other types of single cells. The key insight is concurrent measurement of polynucleic acids derived from small populations of at least two different cell types, such that function in one cell type is linked to the clonal identity of another cell. These methods simultaneously process thousands, millions, or more single cells or small populations of cells. The method integrates molecular, algorithmic, and engineering approaches. This invention has broad and useful application in a number of biological and medical fields, including immunology and drug discovery.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: September 13, 2022
    Assignee: GigaGen, Inc.
    Inventors: David Scott Johnson, Adam Shultz Adler, Matthew James Spindler, Rena Aviva Mizrahi
  • OB-fold used as scaffold for engineering new specific binders
    Patent number: 11434585
    Abstract: The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 6, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frédéric Pecorari, Pedro Alzari
  • Mutant viral capsid libraries and related systems and methods
    Patent number: 11427931
    Abstract: Provided are mutant viral capsid cell libraries, individual cells of such libraries, systems, vectors, and methods for generating the cell libraries, and methods of use thereof to screen for mutant viral capsids with desired characteristics.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 30, 2022
    Assignee: Adverum Biotechnologies, Inc.
    Inventors: Christopher Chavez, Mehdi Gasmi, Annahita Keravala, Thomas W. Chalberg
  • Systems and methods for massively parallel combinatorial analysis of single cells
    Patent number: 11427933
    Abstract: Provided herein are methods that enable parallel evaluation of multiple functional nucleic acids in individual cells or subpopulations of cells, in the context of incubation with other types of single cells. The key insight is concurrent measurement of polynucleic acids derived from small populations of at least two different cell types, such that function in one cell type is linked to the clonal identity of another cell. These methods simultaneously process thousands, millions, or more single cells or small populations of cells. The method integrates molecular, algorithmic, and engineering approaches. This invention has broad and useful application in a number of biological and medical fields, including immunology and drug discovery.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: August 30, 2022
    Assignee: GigaGen, Inc.
    Inventors: David Scott Johnson, Adam Shultz Adler, Matthew James Spindler, Rena Aviva Mizrahi
  • Materials and methods for protein production
    Patent number: 11427932
    Abstract: This document relates to materials and methods for the production of protein. In one aspect, this document provides a nucleic acid construct including a first alcohol oxidase promoter element, wherein the first alcohol oxidase promoter element includes a mutation at one or more nucleotide positions corresponding to any of nucleotide positions 668-734 relative to SEQ ID NO: 28.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 30, 2022
    Assignee: Impossible Foods Inc.
    Inventors: Martin Andrew Hoyt, Xiao Guo, Smita Shankar
  • Methods for labelling, analyzing, detecting and measuring protein-protein interactions
    Patent number: 11421347
    Abstract: The present invention relates generally methods and kits for detecting binding interactions, in particular protein-protein interactions, and particularly to high throughput methods for labelling, analysing, detecting and measuring protein-protein interactions.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 23, 2022
    Assignee: GENEVILLAGE KFT
    Inventor: Csaba Jeney
  • Engineered cells expressing anti-viral T cell receptors and methods of use thereof
    Patent number: 11421220
    Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: August 23, 2022
    Assignee: GigaMune, Inc.
    Inventors: Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio
  • Combinatorial photo-controlled spatial sequencing and labeling
    Patent number: 11421221
    Abstract: Methods of labeling or barcoding molecules within one or more portions of a plurality of cells are provided. Kits and systems for labeling or barcoding molecules within one or more portions of a plurality of cells are also provided. The methods, kits, and systems may utilize photo-controlled adapter sequences, nucleic acids tags, and/or linkers.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: August 23, 2022
    Assignee: University of Washington
    Inventors: Georg Seelig, Anna Kuchina, Alexander B. Rosenberg
  • Affinity resins and sample preparation devices based on cartilaginous fish IgNAR derived binding domains
    Patent number: 11414785
    Abstract: The present disclosure relates to protein arrays and methods of using the same for the detection, quantification and characterization of biomolecules that specifically bind to the array among various other biomolecules in a biological sample. Specifically, the present disclosure relates to protein arrays that include a plurality of immunoglobulin molecules derived from shark single-domain heavy chain antibody lacking light-chains but including at least one variable antigen-binding domain with a binding site for an antigen. The immunoglobulin molecules are immobilized on a substrate via a linker. Further encompassed herein are diagnostic devices and kits, comprising the protein array and methods of using same.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: August 16, 2022
    Assignee: Waters Technologies Corporation
    Inventors: Matthew A. Lauber, Xiaoxiao Liu, Beatrice Muriithi, Edouard S. P. Bouvier
  • Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
    Patent number: 11414784
    Abstract: The invention provides methods and compositions for identifying binding polypeptides (e.g., antibodies or antigen binding fragments thereof) that specifically binds to a cell-surface antigen. The methods of the invention generally comprise contacting a variegated nucleic acid-display library of binding polypeptides with a cell-surface antigen displayed on the exterior surface of a cell; and isolating from the library at least one library member that specifically binds to the cell-surface antigen on the exterior surface of the cell.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: August 16, 2022
    Assignee: X-BODY, INC.
    Inventors: Yan Chen, Steven M. Shamah
  • Fibronectin binding domains with reduced immunogenicity
    Patent number: 11408093
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: August 9, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
  • Stabilized fibronectin based scaffold molecules
    Patent number: 11407815
    Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: August 9, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Dasa Lipovsek
  • Generation of binding molecules
    Patent number: 11408095
    Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 9, 2022
    Assignee: Merus N.V.
    Inventors: Mark Throsby, Ton Logtenberg, John De Kruif